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Abstract
Objectives: Transoral CO2 laser therapy represents the treatment of choice for early-stage laryngeal tumors. The anterior
commissure involvement (ACI) is related to a worse local control and a lower rates of organ preservation. The objective of this
study is to analyze the differences in survival, local control, and organ preservation in T1b glottic patients according to the
presence of ACI. Methods: Observational prospective study in pT1b treated with transoral CO2 laser between 2009 and 2014.
Results: Forty patients (37 male and 3 female) with a mean age of 66.43 + 8.16 years were recruited. Anterior commissure
involvement was present in 70% of the patients. The 5-year specific cause survival was 91.66%, with 32.50% of local recurrences.
Laryngeal preservation was 80%, being lower in the group with local recurrence (P < .000). The involvement of the anterior
commissure does not influence the organ preservation (P ¼ .548), the appearance of local recurrences (P ¼ .391), or the survival
(P¼ .33). Conclusions: Transoral CO2 laser therapy is an effective and reproducible treatment for early-stage laryngeal tumors.
The results obtained are similar to previous studies, although they present discrepancies in relation to the role of the ACI.
Prospective randomized trials are required focusing also on the patients’ quality of life and functional outcome in order to clarify
the role of the ACI and the need to implement changes in its evaluation, staging, and evolution.
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Introduction
Laryngeal squamous cell carcinoma (SCC) is the most common
neoplasm in the head and neck area, and the glottic localization
represents 65% of cases.1 In recent years, this type of tumors has
shown growth in the number of cases and mortality, which is
why his treatment continues to generate debate.1,2
According to the seventh and eighth edition of the TNM-
staging system, T1b is defined as cancer in which both vocal
cords are involved,3,4 and also involves the anterior commis-
sure (AC). Transoral CO2 laser therapy (CO2TOLMS),
5 open
partial surgery, and radiotherapy represent the treatment of
choice for this type of early-stage tumors (T1-T2).6-8 Transoral
CO2 laser therapy approach allows complex resections, preser-
ving disease-free areas, reducing the need for a tracheostomy
and nasogastric tube, as well as obtaining local control of the
disease at 5 years between 70% and 100%.6,9,10
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The AC is considered a laryngeal subsite, but it is not taken
into account in the current T-staging system.3,4 This subsite
rarely corresponds to the origin of glottic tumors (1% laryngeal
tumors), but 20% of glottic tumors show anterior commissure
involvement (ACI).11,12 Its presence and role have been a sub-
ject of debate in recent years, and there is controversy regard-
ing the treatment of early glottic cancer with ACI and it is
related to a worse local control and a lower rates of organ
preservation.9,13 The objective of this study is to analyze the
differences in survival, local control, and organ preservation in
T1b glottic SCC patients treated with CO2TOLMS according
to the presence of ACI.
Methods
Study Design and Data Collection
A descriptive and analytical observational prospective study in
adult patients diagnosed with primary early glottic carcinoma
(pT1bN0M0), who were treated exclusively with CO2TOLMS
in an Otorhinolaryngology–Head and Neck Surgery Depart-
ment of a tertiary university hospital with a minimum follow-
up time of 5 years between 2009 and 2014. The management
and treatment of all patients were discussed in the Hospital’s
Multidisciplinary Head and Neck Oncology Committee. This
research involved human participants and was approved by the
Hospital’s Ethics Committee. Informed consent was obtained
from all individual participants included in the study.
Inclusion criteria were to have a confirmed diagnosis, with
anatomopathological and computed tomography scan radiolo-
gical study,14 of primary pT1bN0M0 glottic carcinoma based
on the Seventh Edition of the American Joint Committee on
Cancer TNM classification system.4 Patients were grouped
according to the existence of ACI or not. Exclusion criteria
were to have synchronous malignancies/distant disease, non-
curative treatment intention, need for conversion to open sur-
gery in the same act, noncandidate patients for transoral
resection, refused/incomplete treatment, and lack of complete
follow-up data (at least 3 months after tumor resection). Exclu-
sion criteria were not applied according to the histological type
of the tumor or patient age.
Sociodemographic variables, local control rate (LCR),
disease-free survival, laryngeal preservation rate (LPR),
salvage surgery, type of laser resection according to the
European Laryngological Society,15 and complications, were
collected. The standard follow-up protocol consists of a clin-
ical examination with endoscopic laryngoscopy on a regular
basis (every 4-6 weeks in the first, every 2-3 months in the
second and third, and every 3-6 months in the fourth and fifth
year, respectively).
Surgical Technique
All procedures were performed with the patient under general
anesthesia. Suspension laryngoscopy was performed, and the
lesion was examined under microscopy (OPMI Vario S88;
Zeiss). Cordectomy type Va or III, according to the European
Laryngological Society classification,15 was performed using
CO2 laser with an AcuSpot 712 Micromanipulator (Lumenis
AcuPulse 30/40W; Adisat), considering an adequate safety
margin when it was at least 2 mm from the tumor. When
required for adequate glottic exposure, a partial vestibulectomy
or Burp maneuver was performed. The surgical specimen was
fixed to a soft board, with the margins marked with ink and sent
for definitive analysis by an experienced surgical pathologist.
No frozen sections were performed.
Statistical Analysis
Statistical analysis was performed with SPSS version 24.0 for
Windows (IBM). Statistical tests were 2 tailed with a 95%
confidence interval. Normality was evaluated by the
Kolmogorov-Smirnov test and variances using the Levene test.
Quantitative variables were expressed as mean + standard
deviation and median. The comparison of means between
groups was performed using the Student t, Mann-Whitney,
analysis of variance, or Kruskal-Wallis test as appropriate.
Qualitative variables were expressed as frequency and percent-
age. The differences between groups were evaluated by the w2
test, Fisher exact test, or its variants as appropriate. Kaplan-
Meier method and further analyzed with the log-rank test for
univariate analysis. Patients with a loss to follow-up were
censored.
Results
A total of 40 patients who met the inclusion criteria were
recruited, 37 male (92.50%) and 3 (7.5%) female. The mean
age was 66.43 + 8.16 years (range: 50-84 years). Anterior
commissure involvement was present in 70% (n ¼ 28) of the
patients and all were treated with Va cordectomy. The 30%
without ACI was treated with type III cordectomy. The patho-
logical result of all resections was SCC.
Follow-Up
The mean time of hospitalization was 1.40 + 0.84 days, and no
postoperative complications were reported. No patient under-
went cervical neck dissection or tracheostomy, nor did they
require nasogastric tube feeding.
The LCR was of 67.5%, with 13 (32.50%) patients in whom
a local recurrence was found. The 61.50% (n¼ 8) of them were
treated with radical surgery (total laryngectomy), 30.75%
(n ¼ 4) with CO2TOLMS, and 7.75% (n ¼ 1) with partial open
surgery (cricohyoidoepiglottopexy). Therefore, the LPR was
80% (n ¼ 32). Analyzing the group with local recurrence, the
LPR was 38.5% (n ¼ 5), there are statistically significant
differences compared to the group without local recurrence
(P < .000). The mean follow-up time until the clinical diagnosis
of local recurrence was 21.26 + 6.55 months, with 53.55% of
these occurring in the first 24 months of follow-up after
CO2TOLMS.
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The role of ACI in local recurrences and organ preserva-
tion was evaluated (Table 1). First, it was found that 77%
(n ¼ 10) with local recurrence had ACI compared to 23%
without ACI. Comparing these results with the group with-
out evidence of local recurrence, which had 66.7% (n ¼ 18)
of ACI, there were no differences (P ¼ .391). Second, no
differences were found in organ preservation according to
the ACI (P ¼ .548).
Survival
The overall survival at 3 and 5 years was 83.7% and 71.9%
(Figure 1), respectively, and the specific cause survival was
94.55% and 91.66% at 3 and 5 years, respectively. Statisti-
cally significant differences were obtained in relation to
specific survival in the group with local recurrences com-
pared to the one that did not present recurrence (P < .000;
Figure 2). Regarding the ACI, no statistically significant
differences were found in relation to the specific cause sur-
vival (P ¼ .33).
Discussion
Laryngeal cancer is the most frequent cancer of the head and
neck in both Europe and the United States, with 65% involve-
ment of the glottic area.1,9 These tumors are generally diag-
nosed early, which can be treated using minimally invasive
therapies like CO2TOLMS, obtaining long-term organ preser-
vation and with good functional results.6,10,16 In the previous
literature, local control has been reported in early stages
between 70% and 100%.9-11,16-18 These data seem to be
explained by the variability in the sample proportions included
according to the TNM-staging system.9
The term early glottic cancer encompasses T1a, T1b, and T2
stages with different characteristics and that seem to have a
different evolution. For this reason, research focused on each
stage has been carried out in recent years.9,19 Specifically, T1b
and ACI are the objects of anatomic, diagnostic, and therapeutic
controversies in laryngeal oncology.20 This study represents one
of the largest cohorts with T1b cancer involving the AC to date.
The eighth edition of the TNM staging system introduced
major changes for some cancers. However, the staging of lar-
yngeal tumors has not undergone any change yet.3,4 Among the
small number of reports, including more than 30 patients with
ACI treated by endoscopic laser cordectomy,9 most have
described poorer oncological outcomes for these tumors com-
pared to those sparing the AC.9,16,21 Likewise, the few studies
focused specifically in T1b patients seem to present signifi-
cantly lower results in relation to LCR and survival compared
to previous studies that analyzed the set of early glottic
cancer.13,18 Despite this, the conclusions are not unanimous and
the role of the ACI continues to be controversial.9,22 To date,
there are no prospective reports in this regard, so the objective
of this study was to analyze the differences in survival, local
control, and organ preservation in T1b glottic SCC patients
treated with CO2TOLMS according to the presence of ACI.
Table 1. Role of the Anterior Commissure Involvement in Local
Recurrence and Laryngeal Preservation.
Yes, n (%) No, n (%) OR P value
Local recurrence 13 (32.5) 27 (67.5) – –
With ACI 10 (77) 18 (66.7) 1.67 .391
Without ACI 3 (23) 9 (33.3)
Laryngeal preservation 32 (80) 8 (20) – –
With ACI 22 (68.5) 6 (75) 0.74 .548
Without ACI 10 (31.5) 2 (25)
With local recurrence 5 (38.5) 8 (61.5) 0 <.000
Without local recurrence 27 (100) 0
Abbreviations: ACI, anterior commissure involvement; OR, odds ratio.
Figure 1. Overall survival at 3 and 5 years.
Figure 2. Specific cause survival depending on the presence (green
line) or not (blue line) of local recurrence.
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The findings in relation to ACI in our population are similar
to previous studies in which an affectation of 69% was found.17
The overall and specific survival are also similar to the data
described in the previous literature, with values greater than
80% at 3 and 5 years, and without differences in relation to the
ACI.7,16,17,19 While the early-stage glottic carcinoma without
AC infiltration treated by CO2TOLMS shows excellent onco-
logic and functional outcomes, with recurrence rates similar to
our work and typically range from 15% to 30%,17,19 the carci-
noma with AC infiltration is often associated with a worse
clinical course.11,16,17 This might be due to a higher rate of
local recurrence compared to the carcinomas that are solely
placed on the vocal chords. In fact, the influence of local recur-
rence on the survival found in our cohort is remarkable, being
significantly less in the group of these patients. Despite this, no
differences were found in the local recurrence rate in relation to
the ACI.
In relation to organ preservation, our data are similar to
previous literature where rates from 80% to 100% for early-
stage glottic tumors have been reported, although it can be
improved.17,23 This fact has been related to various factors such
as the inclusion of T1a, T1b, and T2 in the statistical analysis or
the ability of T1b to progress into circumscribed T4a tumors
due to thyroid cartilage involvement in a short period of time
(Figure 3), which represents a contraindication for
CO2TOLMS. Hence, some authors even claimed a modified
tumor staging classification addressing ACI.24 The Broyles’s
ligament is a weak structure of the AC resulting in peculiar
progression pathways of cartilage invasion due to local dehis-
cence of perichondrium at its insertion point. A CO2TOLMS in
T1b glottic SCC demands conditions and superior surgical and
anatomical skills from an oncological safety point of view,
being necessary to contemplate other treatment modalities such
as open partial surgeries or radiotherapy in some lesions with
ACI and poor laryngeal exposure.7,8,11,18,25 These treatment
modalities present equivalent oncological results, being in the
morbidity and functional results where the differences reside.
In this sense, advances in endoscopic surgery,26 implementing
the flexible diode laser,27 or through transoral robotic surgery28
have been proposed in order to decrease morbidity and improve
tumor exposure.
We must reflect on surveillance and the need for early regu-
lated radiological control in the first postoperative months in
order to improve the organ preservation rate.9,14,19 Likewise,
Piazza et al emphasized the need for more detailed staging of
early glottic cancer into 6 subcategories to better cope with the
wide spectrum of distinct local tumor spread. For this purpose,
they classified the range from tumors infiltrating 1 vocal cord
to those with horizontal spread to the vocal muscle/paraglottic
space, or those with a vertical trans-AC extension with an
invasion of the anterior pre-epiglottic/paraglottic space.24
Conclusion
In conclusion, we present the first prospective data described
regarding a homogeneous group of exclusively CO2TOLMS-
treated T1b glottic carcinoma patients in which the role of the
ACI has been evaluated. According to our results, this is an
effective and reproducible treatment for this type of lesions,
with similar results to previous studies and comparable with
other therapeutic modalities.8,9,11,21,22 Despite this, prospective
randomized trials are required focusing also on the patients’
quality of life and functional outcome in order to clarify the
role of the ACI and the need to implement changes in its
evaluation, staging, and evolution.
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Figure 3. A, Computed tomography scan with T1b glottic tumor with involvement of the anterior commissure. B, T4a recurrence 1 year later,
with thyroid cartilage involvement. C, Total laryngectomy due to this recurrence where transglottic extension can be seen.
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Henrı́quez CC, Yáñez MM, Sistiaga Suarez JA. CO2 transoral
laser microsurgery in benign, premalignant and malignant (Tis,
T1, T2) lesion of the glottis. A literature review. Medicines
(Basel). 2019;6(3).
7. Higgins KM, Shah MD, Ogaick MJ, Enepekides D. Treatment of
early-stage glottic cancer: meta-analysis comparison of laser exci-
sion versus radiotherapy. J Otolaryngol Head Neck Surg. 2009;
38(6):603-612.
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